Review articleTopical antibacterial therapy for mycobacterial keratitis: Potential for surgical prophylaxis and treatment
References (32)
- et al.
Nontuberculous mycobacterial keratitis in South Florida
Ophthalmology
(1998) - et al.
Mycobacterium fortuitum as a cause of corneal ulcer
Am J Ophthalmol
(1965) - et al.
Bilateral infectious keratitis after laser in situ keratomileusis: A case report and review of the literature
Ophthalmology
(2001) - et al.
Mycobacterium fortuitum keratitis
Am J Ophthalmol
(1988) - et al.
A cluster of cases of Mycobacterium chelonei keratitis associated with outpatient office procedures
Am J Ophthalmol
(1984) - et al.
Mycobacterium chelonei keratitis after radial keratotomy
Am J Ophthalmol
(1986) - et al.
Postoperative mycobacterial endophthalmitis
Am J Ophthalmol
(1989) - et al.
A case report of Mycobacterium chelonae keratitis and a review of mycobacterial infections of the eye and orbit
Tuber Lung Dis
(1994) - et al.
Comparison of topical antibiotics for treating Mycobacterium fortuitum keratitis in an animal model
Am J Ophthalmol
(1993) - et al.
Mycobacterium chelonei keratitis
Am J Ophthalmol
(1982)
Mycobacterium chelonae keratitis
Am J Ophthalmol
Nontuberculous mycobacterial keratitis: A study of 22 cases
Br j Ophthalmol
Keratitis due to Mycobacterium chelonei
Tubercle
Mycobacterium chelonae conjunctivitis and scleritis following vitrectomy
Arch Ophthalmol
Microbial keratitis after laser in situ keratomileusis
J Refract Surg
Intrascleral dissemination of infectious scleritis following pterygium excision
Br j Ophthalmol
Cited by (53)
Discovery of novel antimycobacterial drug therapy in biofilm of pathogenic nontuberculous mycobacterial keratitis
2017, Ocular SurfaceCitation Excerpt :Therefore, we investigated the fate of mycobacteria in a murine model of corneal infection and report our findings herein. Medical treatments of NTM infections are often unsuccessful, possibly due to biofilm formation [24] or variable in vitro antibiotic sensitivities for different strains of NTM [26]. Amikacin has been the agent of choice for treatment of most NTM infections and may be a clinical gold standard [27].
Mycobacteriological characteristics and treatment outcomes in extrapulmonary Mycobacterium abscessus complex infections
2017, International Journal of Infectious DiseasesCitation Excerpt :The most common causative organism is Mycobacterium chelonae, with MABC accounting for 10% of NTM ocular infections (Kheir et al., 2015). Some patients recover fully after antibiotic treatment, whereas others need therapeutic surgical interventions (Kheir et al., 2015), and unlike other extrapulmonary NTM infections, NTM ocular infections can be successfully treated with topical antibiotics (Abshire et al., 2004). MABC is traditionally considered to be resistant to multiple antibiotics, and data supporting effective drugs or regimens are very limited.
Nontuberculous Mycobacterial Ocular and Adnexal Infections
2012, Survey of OphthalmologyInfectious keratitis outbreak after laser in situ keratomileusis at a single laser center in Japan
2011, Journal of Cataract and Refractive SurgeryOral moxifloxacin and topical amikacin for Mycobacterium abscessus keratitis after laser in situ keratomileusis
2010, Journal of Cataract and Refractive SurgeryCitation Excerpt :The normal host defense against this organism is thought to be strong because exposure is universal and related disease rare.2 Mycobacterium abscessus keratitis after LASIK is a severe infection with a frequently delayed diagnosis, slow resolution, and difficult treatment that often involves the need for surgical intervention (eg, lamellar keratoplasty, flap removal, flap irrigation with antibiotic agents).3 This is due to the highly invasive nature of the pathogen, which has the ability to deeply penetrate the collagen layers of the cornea.
Efficacy of moxifloxacin in treating bacterial conjunctivitis: A meta-analysis
2010, Journal Francais d'Ophtalmologie